Zimmer Biomet Holdings, Inc.
NYSE:ZBHMedical - Devices
+$0.87 today
- Market cap
- $19.55B
- Beta
- 0.47
- P/E (TTM)
- 22.5
- EPS (TTM)
- $3.90
- Dividend yield
- 1.09%
Volume 2.34M
Average 2.28M
ZBH Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Zimmer Biomet Holdings, Inc.NYSE: ZBH
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income growth accelerates
Q2 FY2026 net income of $199.6M rose 30.1% year over year, ahead of the -2.0% change in trailing-twelve-month net income. Sequentially, it fell 16.2% from the prior quarter. Over 3 fiscal years it compounded at +34.3% a year.
Context
- Net income amounted to 8.6% of revenue in FY2025, down 3.2 pp from a year earlier.
- Net income increased in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 19 analysts of $1.7B (+140.9%) for the fiscal year ending Dec 2026, a step up from the -22.1% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $199.6M-16.2% QoQ
- Last fiscal yearDec 2025
- $705.1M-22.1% YoY
- LTMJun 2026
- $808.5M-2.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +30.1% | +55.7% | +25.6 pp |
| 1 year | -22.1% | +140.9% | +163.0 pp |
| 3-year CAGR | +34.3% | +37.2% | +2.9 pp |
| 5-year CAGR | +24.8% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 705.1M USD
- Year-over-year change
- -22.1%
- 4-year CAGR
- +12.2%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 705.1M | -22.1% |
| FY2024 | 2024-12-31 | 905.2M | -11.7% |
| FY2023 | 2023-12-31 | 1.03B | +252.0% |
| FY2022 | 2022-12-31 | 291.2M | -34.6% |
| FY2021 | 2021-12-31 | 445.5M | — |
Net Income vs competitors
How ZBH compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -2.0% is the 7th highest of 10, against a peer median of +24.5%.
- Net income amounts to 9.5% of revenue for ZBH, versus a peer median of 14.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $5.27B USD | +12.7% | +8.5% | 14.0% | |
| LTM Jun 2026 | $3.73B USD | +27.8% | +11.2% | 14.4% | |
| LTM Jun 2026 | $3.67B USD | +34.6% | +60.6% | 17.5% | |
| LTM Jun 2026 | $2.04B USD | -12.0% | +3.4% | 10.1% | |
| LTM Jun 2026 | €1.12B EUR | +541.7% | — | 6.3% | |
| LTM Jun 2026 | $1B USD | -75.8% | -11.1% | 15.4% | |
| LTM Jun 2026 | $808.5M USD | -2.0% | +34.3% | 9.5% | |
| FY2025 | $625M USD | +51.7% | +41.0% | 10.1% | |
| LTM Jun 2026 | $192.51M USD | -12.4% | +4.3% | 4.7% | |
| LTM Mar 2026 | $178.05M USD | +24.5% | +67.1% | 21.6% | |
| Peer median (excluding ZBH) | — | +24.5% | +9.9% | 14.0% | |
Competitors are the stored peer set for ZBH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 445.5M | 291.2M | 1.03B | 905.2M | 705.1M |
| Depreciation & Amortization | 937.7M | 926.4M | 951.7M | 996.3M | 1.09B |
| Deferred Income Tax | (102.1M) | (64.4M) | (96.3M) | (47.7M) | (87.2M) |
| Stock-Based Compensation | 76M | 105M | 99.8M | 101M | 90.2M |
| Change in Working Capital | (134.2M) | (311.4M) | (396.2M) | (455.4M) | (104.9M) |
| Accounts Receivables | (40.8M) | (184.7M) | (51.9M) | (89.7M) | (127.3M) |
| Inventory | (8.4M) | (75.6M) | (240.4M) | 49.9M | 98.2M |
| Accounts Payables | 86.5M | 103M | (55.3M) | (322M) | 101.8M |
| Other Working Capital | (171.5M) | (154.1M) | (48.6M) | (93.6M) | (177.6M) |
| Other Non-Cash Items | 276.3M | 337.9M | (2.5M) | 0 | 100K |
| Operating Cash Flow | 1.5B | 1.28B | 1.58B | 1.5B | 1.7B |
| Capital Expenditures | (152M) | (217.6M) | (394.5M) | (356.8M) | (224.5M) |
| Acquisitions (Net) | 0 | (99.8M) | (134.9M) | (276.3M) | (1.39B) |
| Purchases of Investments | (273.6M) | (258.3M) | (311.7M) | (240.3M) | (300.5M) |
| Sales of Investments | 1.9M | 89.4M | 33.4M | 22.1M | 0 |
| Other Investing Activities | (88.3M) | (72.6M) | (74.6M) | (189.8M) | (57.5M) |
| Investing Cash Flow | (503.6M) | (529.2M) | (778.9M) | (888.1M) | (1.98B) |
| Debt Repayment | (1.06B) | (1.06B) | 54.6M | 536.3M | 1.03B |
| Common Stock Issued | 122.5M | 0 | 0 | 0 | 39.7M |
| Common Stock Repurchased | 0 | (126.4M) | (692.2M) | (868M) | (487M) |
| Dividends Paid | (200.1M) | (201.2M) | (200.9M) | (196M) | (190.3M) |
| Other Financing Activities | (173.4M) | 544.5M | 75M | 43.2M | (65.5M) |
| Financing Cash Flow | (1.31B) | (843.8M) | (763.5M) | (484.5M) | 326M |
| Effect of Forex Changes | (13.2M) | (14.5M) | 900K | (17.1M) | 19M |
| Net Change in Cash | (323.6M) | (102.8M) | 40.1M | 109.7M | 66.4M |
| Free Cash Flow | 1.35B | 1.07B | 1.19B | 1.14B | 1.47B |
Zimmer Biomet Holdings, Inc.
NYSE:ZBH
Intrinsic Alpha fair value
Locked
Current Price
$103.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.